Protalix BioTherapeutics (PLX) Total Non-Current Liabilities (2010 - 2026)

Protalix BioTherapeutics' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $7.7 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 76.96% year-over-year to $7.7 million in Q1 2026; TTM through Mar 2026 was $7.7 million, a 76.96% increase from a year earlier, with the FY2025 full-year figure at $7.6 million, up 65.71% from the prior year.
• Total Non-Current Liabilities advanced to $7.7 million in Q1 2026 per PLX's latest filing, from $7.6 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $40.5 million in Q1 2022 and bottomed at $4.4 million in Q1 2025.
• The 5-year median for Total Non-Current Liabilities is $7.4 million (2025), against an average of $15.9 million.
• Across the five-year window, Total Non-Current Liabilities soared 445.93% in 2022 and tumbled 84.69% in 2024, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $34.0 million in 2022, then plunged by 84.31% to $5.3 million in 2023, then dropped by 14.06% to $4.6 million in 2024, then surged by 65.71% to $7.6 million in 2025, then increased by 1.59% to $7.7 million in 2026.
• Per Business Quant, the three latest PLX Total Non-Current Liabilities figures stand at $7.7 million (Q1 2026), $7.6 million (Q4 2025), and $7.4 million (Q3 2025).